{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:40:07Z","timestamp":1778121607042,"version":"3.51.4"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Thoracic empyema and concomitant bronchopleural fistula are serious complications of pneumonia. The treatment of empyema caused by extensively drug-resistant <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic> (XDR-PA) has become increasingly challenging.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient's concerns and important clinical findings:<\/jats:title>\n            <jats:p>A 57-year-old woman with controlled schizophrenia developed hospital-associated bacterial pneumonia secondary to <jats:italic toggle=\"yes\">P. aeruginosa<\/jats:italic> on day 13 of hospitalization for brain meningioma surgery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Chest radiography and computed tomography revealed right-sided necrotizing pneumonia with pneumothorax, a focal soft tissue defect over the right lower chest wall, and a mild right-sided encapsulated pleural effusion with consolidation. XDR-PA was isolated on empyema cultures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>The patient was treated with intrapleural amikacin as a bridge to video-assisted thoracoscopic surgery, followed by novel ceftazidime-avibactam therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>On the 104th day of admission, the patient underwent chest wall debridement and closure. The patient was discharged on day 111. Twenty-eight days after discharge, there were no observable sequelae of empyema.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Although the minimum inhibitory concentration of ceftazidime-avibactam for XDR-PA is relatively high (8\u200amg\/L), this report emphasizes the efficacy of ceftazidime-avibactam treatment for XDR-PA empyema, as well as the importance of source control.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029467","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T13:09:59Z","timestamp":1655471399000},"page":"e29467","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Ceftazidime-avibactam and intrapleural amikacin therapy for extensively drug-resistant Pseudomonas aeruginosa thoracic empyema"],"prefix":"10.1097","volume":"101","author":[{"given":"Tzu-Ting","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Mei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan"},{"name":"Department of Surgery, School of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"Division of Infection Diseases, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"R1-20250612","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s12879-021-06153-0","article-title":"In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018)","volume":"21","author":"Pi\u00e9rard","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R2-20250612","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review","volume":"10","author":"Soriano","year":"2021","journal-title":"Infect Dis Ther"},{"key":"R3-20250612","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3390\/antibiotics10091126","article-title":"Review of ceftazidime-avibactam for the treatment of infections caused by Pseudomonas aeruginosa","volume":"10","author":"Daikos","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R4-20250612","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiz149","article-title":"Ceftazidime-avibactam in combination with fosfomycin: a novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa","volume":"220","author":"Papp-Wallace","year":"2019","journal-title":"J Infect Dis"},{"key":"R5-20250612","doi-asserted-by":"crossref","first-page":"e01018","DOI":"10.1128\/AAC.01018-18","article-title":"Colistin does not potentiate ceftazidime-avibactam killing of carbapenem-resistant enterobacteriaceae in vitro or suppress emergence of ceftazidime-avibactam resistance","volume":"62","author":"Shields","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20250612","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s41030-020-00140-7","article-title":"Management of pleural infection","volume":"7","author":"Sundaralingam","year":"2021","journal-title":"Pulm Ther"},{"key":"R7-20250612","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.2147\/IJGM.S292705","article-title":"Recent insights into the management of pleural infection","volume":"14","author":"Hassan","year":"2021","journal-title":"Int J Gen Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029467","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:00:49Z","timestamp":1749754849000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029467"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":7,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029467","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"assertion":[{"value":"2022-03-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}